Efficient synthesis of pyropheophorbide a and its derivatives

Information

  • Patent Grant
  • 7053210
  • Patent Number
    7,053,210
  • Date Filed
    Wednesday, July 2, 2003
    21 years ago
  • Date Issued
    Tuesday, May 30, 2006
    18 years ago
Abstract
A process for the preparation of pyropheophorbide a and its derivatives, including 3-devinyl-3-(1′-hexyloxy)ethyl-pyropheophorbide-a, otherwise known as HPPH, is provided. The process involves treating chlorin e6, in the form of its trimethyl ester, with a base, followed by heating to give pyropheophorbide a, which is converted to HPPH by treatment with acid, followed by hexyl alcohol under basic conditions.
Description
FIELD

Provided herein is a process for the preparation of pyropheophorbide a and its derivatives, including hexyloxy pyropheophorbide a, otherwise known as HPPH. The process involves treating chlorin e6, in the form of its trimethyl ester, with a base, followed by heating to give pyropheophorbide a, which is converted to HPPH by treatment with hexyl alcohol under acidic conditions.


BACKGROUND

Photodynamic therapy (PDT) is relatively a new treatment method for the destruction of tumors. PDT is based on the accumulation in malignant tissue of a photosensitizer after its administration. Subsequent illumination with light of an appropriate wavelength creates a photochemical reaction, a so-called photodynamic effect (photochemical reaction producing singlet oxygen) that results in tumor destruction.


It is well established that both absorption and scattering of light by tissue increases as the wavelength decreases, and that the most effective sensitizers are those that have strong absorption bands between 660–800 nm. In recent years, a series of photosensitizers have been developed related to pyropheophorbide-a and purpurinimides (obtained from purpurin-18) with a variable lipophilicity exhibiting the longer wavelength absorption at 665 and 705 nm (in vivo absorption) respectively.


Historically, preparation of HPPH has required the isolation of methyl pheophorbide a from Spirulina Algae by cryogenic fracturing of the cells followed by extraction, chromatographic purification, and recrystallization. See, e.g., U.S. Pat. No. 5,198,460 and references cited therein. The methyl pheophorbide a obtained in this way was then separately subjected to thermal decarboxylation in collidine at reflux temperature. Following this treatment, the resulting methyl pyropheophorbide a was treated with hexyl alcohol and acid to form the hexyl ether moiety. Finally, the methyl ester was removed by saponification to give HPPH. Thus, four rather laborious steps were required in order to obtain HPPH. This procedure works well in the laboratory scale preparation where the final product is required in small amounts. However, the purification of the intermediates at several stages of the synthesis requires column chromatography. Therefore, there is a need for an alternate synthesis of HPPH suitable for large-scale synthesis.


SUMMARY

Provided herein is a synthetic process for the preparation of hexyloxy pyropheophorbide a and related compounds. The process is suitable for large scale (i.e., multigram to multi-kilogram or more) production of such compounds.


The process provided herein affords the desired product in higher yield and/or purity than known processes. Also, the process provided herein avoids the use of chromatographic purification of intermediates and/or desired product.







DETAILED DESCRIPTION

A. Definitions


Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of ordinary skill in the art. All patents, applications, published applications and other publications are incorporated by reference in their entirety. In the event that there are a plurality of definitions for a term herein, those in this section prevail unless stated otherwise.


As used herein, “methyl pheophorbide a” refers to:




embedded image


As used herein, “chlorin e6 trimethyl ester” refers to:




embedded image


As used herein, an “aromatic solvent” is an organic compound having an aromatic nucleus.


As used herein, “pyropheophorbide a” refers to:




embedded image


As used herein, a “high boiling aromatic solvent” refers to an aromatic solvent, as defined herein, that has a boiling point high enough to effect decarboxylation of the following compound at reflux:




embedded image



In certain embodiments herein, the boiling point of a high boiling aromatic solvent is greater than 115° C., 120° C., 125° C., 130° C., 135° C., 140° C., 145° C., 150° C., 155° C., 160° C., 165° C. or 170° C.


As used herein, “ether analogs of pyropheophorbide a” refers to compounds of the general formula:




embedded image



where R is alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl, and is unsubstituted or substituted with one or more substituents, in one embodiment one to five substituents, in another embodiment one, two or three substituents, each independently selected from halo, pseudohalo, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, hydroxy, alkoxy, aryloxy, carboxy, aralkoxy, sulfones, amines, amides and sulfonamides.


As used herein, “purpurin-18” is:




embedded image


As used herein, a “base” is an inorganic or organic compound sufficiently basic to effect a Dieckmann condensation. In certain embodiments, the base is an organic compound. In other embodiments, the base has a pKa of the corresponding protonated form of less than about 15, 10, 8 or 5, relative to water.


As used herein, “ether analogs of pururin-18” refers to compounds of the general formula:




embedded image



where R is alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl, and is unsubstituted or substituted with one or more substituents, in one embodiment one to five substituents, in another embodiment one, two or three substituents, each independently selected from halo, pseudohalo, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, hydroxy, alkoxy, aryloxy, carboxy, aralkoxy, sulfones, amines, amides and sulfonamides.


As used herein, a “purpurinimide” is a compound of the general formula:




embedded image



where R is alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl, and is unsubstituted or substituted with one or more substituents, in one embodiment one to five substituents, in another embodiment one, two or three substituents, each independently selected from halo, pseudohalo, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, hydroxy, alkoxy, aryloxy, carboxy, aralkoxy, sulfones, amines, amides and sulfonamides.


As used herein, “ether analogs of purpurinimides” refers to compounds of the general formula:




embedded image



where R is independantly alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl or heteroaryl, and is unsubstituted or substituted with one or more substituents, in one embodiment one to five substituents, in another embodiment one, two or three substituents, each independently selected from halo, pseudohalo, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, hydroxy, alkoxy, aryloxy, carboxy, aralkoxy, sulfones, amines, amides and sulfonamides.


As used herein, an “acid” is an inorganic or organic compound of sufficient acidity to effect addition of an alcohol to a vinyl group. In one embodiment, an acid is an inorganic compound. In another embodiment, an acid has sufficient acidity to effect addition of an alcohol to a vinyl group directly attached to an aromatic porphyrin nucleus.


As used herein, the term “porphyrin” refers to a cyclic structure typically composed of four pyrrole rings, and refers to a porphyrin or porphyrin derivative. Such derivatives include porphyrins with extra rings ortho-fused, or ortho-perifused, to the porphyrin nucleus, porphyrins having a replacement of one or more carbon atoms of the porphyrin ring by an atom of another element (skeletal replacement), derivatives having a replacement of a nitrogen atom of the porphyrin ring by an atom of another element (skeletal replacement of nitrogen), derivatives having substituents other than hydrogen located at the peripheral (meso-, β-) or core atoms of the porphyrin, derivatives with saturation of one or more bonds of the porphyrin (hydroporphyrins, e.g., chlorins, bacteriochlorins, isobacteriochlorins, decahydroporphyrins, corphins, pyrrocorphins, etc.), derivatives obtained by coordination of one or more metals to one or more porphyrin atoms (metalloporphyrins), derivatives having one or more atoms, including pyrrolic and pyrromethenyl units, inserted in the porphyrin ring (expanded porphyrins), derivatives having one or more groups removed from the porphyrin ring (contracted porphyrins, e.g., corrin, corrole) and combinations of the foregoing derivatives (e.g phthalocyanines, porphyrazines, naphthalocyanines, subphthalocyanines, and porphyrin isomers).


As used herein, “chlorin” refers to a class of porphyrin derivatives having a cyclic structure typically composed of four pyrrole rings having one partially saturated pyrrole ring, such as the basic chromophore of chlorophyll.


As used herein, alkyl, alkenyl and alkynyl carbon chains, if not specified, contain from 1 to 20 carbons, or 1 or 2 to 16 carbons, and are straight or branched. Alkenyl carbon chains of from 2 to 20 carbons, in certain embodiments, contain 1 to 8 double bonds and alkenyl carbon chains of 2 to 16 carbons, in certain embodiments, contain 1 to 5 double bonds. Alkynyl carbon chains of from 2 to 20 carbons, in certain embodiments, contain 1 to 8 triple bonds, and the alkynyl carbon chains of 2 to 16 carbons, in certain embodiments, contain 1 to 5 triple bonds. Exemplary alkyl, alkenyl and alkynyl groups herein include, but are not limited to, methyl, ethyl, propyl, isopropyl, isobutyl, n-butyl, sec-butyl, tert-butyl, isopentyl, neopentyl, tert-pentyl, isohexyl, allyl (propenyl) and propargyl (propynyl). As used herein, lower alkyl, lower alkenyl, and lower alkynyl refer to carbon chains having from about 1 or about 2 carbons up to about 8 carbons.


As used herein, halogen refers to one of the electronegative elements of group VIIA of the periodic table (fluorine, chlorine, bromine, iodine, astatine).


As used herein, “hydroxy group” generally refers to a hydroxyl group having the formula —OH.


As used herein, “carboxy” generally refers to the radical —C(O)OH.


As used herein, “ester group” generally refers to a substituent of the general formula —C—O—O—R1 where R1 may be either aliphatic or aromatic.


As used herein, “aromatic group” generally refers to a ring structure having cyclic clouds of delocalized π electrons above and below the plane of the molecule, where the π clouds contain (4n+2) π electrons. A further discussion of aromaticity is found in Morrison and Boyd, Organic Chemistry, (5th Ed., 1987), Chapter 13, entitled “Aromaticity,” pages 477–497, incorporated herein by reference.


As used herein, “amide group” generally refers to the group —C(O)NRR where each R is independently aliphatic or aromatic.


As used herein, “amine group” has the general formula —NRR, where each R is independently any alkyl or aryl group.


As used herein, “cycloalkyl” refers to a saturated mono- or multi-cyclic ring system, in certain embodiments of 3 to 20 carbon atoms, in other embodiments of 3 to 10 carbon atoms. The ring systems of the cycloalkyl groups may be composed of one ring or two or more rings which may be joined together in a fused, bridged or spiro-connected fashion.


As used herein, “aryl” refers to aromatic monocyclic or multicyclic groups containing from 6 to 19 carbon atoms. Aryl groups include, but are not limited to groups such as unsubstituted or substituted fluorenyl, unsubstituted or substituted phenyl, and unsubstituted or substituted naphthyl.


As used herein, “heteroaryl” and “heteroaromatic group” refers to a monocyclic or multicyclic aromatic ring system, in certain embodiments, of about 5 to about 20 members where one or more, in one embodiment 1 to 3, of the atoms in the ring system is a heteroatom, that is, an element other than carbon, including but not limited to, nitrogen, oxygen or sulfur. The heteroaryl group may be optionally fused to a benzene ring. Heteroaryl groups include, but are not limited to, furyl, imidazolyl, pyrimidinyl, tetrazolyl, thienyl, pyridyl, pyrrolyl, thiazolyl, isothiazolyl, oxazolyl, isoxazolyl, triazolyl, quinolinyl and isoquinolinyl.


As used herein, “heterocyclyl” refers to a monocyclic or multicyclic non-aromatic ring system, in one embodiment of 3 to 20 members, in another embodiment of 4 to 10 members, in a further embodiment of 5 to 6 members, where one or more, in certain embodiments, 1 to 3, of the atoms in the ring system is a heteroatom, that is, an element other than carbon, including but not limited to, nitrogen, oxygen or sulfur. In embodiments where the heteroatom(s) is(are) nitrogen, the nitrogen is optionally substituted with alkyl, alkenyl, alkynyl, aryl, heteroaryl, aralkyl, heteroaralkyl, cycloalkyl, heterocyclyl, cycloalkylalkyl, heterocyclylalkyl, acyl, guanidino, or the nitrogen may be quaternized to form an ammonium group where the substituents are selected as above.


As used herein, “aralkyl” refers to an alkyl group in which one of the hydrogen atoms of the alkyl is replaced by an aryl group.


As used herein, “heteroaralkyl” refers to an alkyl group in which one of the hydrogen atoms of the alkyl is replaced by a heteroaryl group.


As used herein, “halo”, “halogen” or “halide” refers to F, Cl, Br or I.


As used herein, pseudohalides or pseudohalo groups are groups that behave substantially similar to halides. Such compounds can be used in the same manner and treated in the same manner as halides. Pseudohalides include, but are not limited to, cyanide, cyanate, thiocyanate, selenocyanate, trifluoromethoxy, and azide.


All chemical compounds include both the (+) and (−) stereoisomers, as well as either the (+) or (−) stereoisomer, and also all diastereomers, rotamers and geometric isomers.


B. Process for Preparing Pyropheophorbide a and its Derivatives


The process provided herein, depicted below, avoids a number of shortcomings of the prior art by resorting to another source as the raw material. Chlorin e6 trimethyl ester undergoes a Dieckmann Condensation to form the additional exocyclic ring, sometimes called an “E-ring”, which is present in the pheophorbides, and chlorophyll itself for that matter. See, e.g., Schaefer, J. P.; Bloomfield, J. J. Org. React. 1967, 15, 1–203; and Davis, B. R.; Garrett, P. J. Comp. Org. Syn. 1991, 2, 806–829. This reaction has traditionally been performed in aromatic solvents, originally benzene, but later toluene and others for safety reasons. In the case of chlorin e6 and compounds like it, pyridine has been used for this purpose. See, e.g., Smith, K. M.; Bisset, G. M. F.; Bushell, M. J. J. Org. Chem. 1980, 45, 2218–2224. These workers did not use chlorin e6 itself, but a similar compound in which a methyl group substituent was present at position 5, the δ “meso” position.




embedded image


In order to improve the performance of this reaction, the pyridine was replaced with a more substituted analog in order to raise the boiling point of the reaction mixture. Thus, collidine, also called sym-collidine (for symmetrical, see below) or 2,4,6-trimethylpyridine, was used. Other basic aromatic solvents, including but not limited to 2,6-lutidine, could also be used. In this way the temperature of reflux of the reaction mixture is altered—the boiling point of pyridine is 115° C., while that of collidine is 172° C. By raising the temperature of the reaction mixture after completion of the Dieckmann Condensation, it is possible to bring about the subsequent thermal decarboxylation without any intervening purification or unnecessary manipulation of the reaction mixture. As a further benefit, it was found that, under the strongly basic conditions employed to carry out the Dieckmann Condensation, the methyl ester of the pheophorbide system also undergoes cleavage, thus accomplishing three chemical transformations in a single treatment.




embedded image


Basic Aromatic Solvents

The pheophorbide a obtained in this way need only be converted to its hexyl ether in order to produce HPPH. This can be done in much the same way as it was done in the older synthesis, giving an overall two-pot preparation of this product.


Since many other compounds can also be obtained from pyropheophorbide a (see below), this new process affords greatly simplified access to all such compounds. These compounds include purpurin-18 and its derivatives, especially the ethers made from the vinyl group in an analogous manner to the hexyl ether in HPPH, and the purpurinimide series. In these examples, one would omit the high temperature treatment and thermal decarboxylation in order to retain the carboxyl group for the construction of the expanded E-ring used in these systems.




embedded image


The following examples are included for illustrative purposes only and are not intended to limit the scope of the subject matter claimed herein.


EXAMPLE 1

Preparation of Pyropheophorbide-a


Chlorin e6 trimethyl ester (350 mg) was dissolved in dry 2,4,6-collidine (30 mL) and then carefully degassed with nitrogen at 50° C. under vacuum. Potassium tert-butoxide (Aldrich, 5.0 mL, 1 M) was added. The initial bright green color immediately turned orange and the reaction mixture was left stirring at room temperature for 20 min. It was then quenched with degassed glacial acetic acid (10 mL). The flask was then connected to a small distillation assembly (condenser, receiving head and a flask), the acetic acid along with a small amount of collidine (5 mL) were removed under high vacuum. The distillation assembly was dismantled and fresh collidine (15 mL) was added. The reaction flask was then connected to a condenser, and the reaction mixture was heated at reflux under nitrogen for 2 hours. The solvent was removed under high vacuum. The residue so obtained was re-dissolved in dichloromethane (100 mL), washed with water (2×100 mL) and dried over anhydrous sodium sulfate. Evaporation of the solvent gave pyropheophorbide-a (as carboxylic acid) in 85% yield after crystallization. 1H NMR (CDCl3, δ ppm): 9.35 and 9.15 and 8.50 (each s, 1H, meso H); 7.80 (m, 1H, CH═CH2); 6.25, 6.10 (each d, 1H, CH—CH2); 5.22 (dd, 2H, —CH2, exocyclic ring); 4.41 (q, 1H, 18H); 4.28 (d, 1H, 17-H); 3.75 (q, 2H, CH2CH3 merged with one of the ring CH3); 3.62, 3.35 and 3.10 (each s, 3H, ring CH3); 2.80–2.10 (several m, CH2CH2CO2H); 1.80 (d, 3H, 18-CH3): 1.60 (t, 3H, CH2CH3); −1.78 (each s, 1H, NH).


EXAMPLE 2

3-Devinyl-3-(1′-hexyloxy)ethyl-pyropheophorbide-a (HPPH)


Pyropheophorbide-a (100 mg) was taken in a 50 mL round bottom flask and 30% HBr/HOAc (Aldrich, 2.0 mL) was added. The reaction mixture was stirred at room temperature for 2 hour and the solvent was removed under high vacuum (bath temperature was maintained at 30–40° C.). It was re-dissolved in dry dichloromethane (10 mL). Hexanol (2.00 mL), potassium carbonate (200 mg) were added, and the reaction mixture was stirred at room temperature for 45 min under nitrogen atmosphere. It was poured in water (100 mL), extracted with dichloromethane. The organic layer was washed with water and dried over anhydrous sodium sulfate. Evaporation of the solvent gave a residue that was crystallized from dichloromethane/hexane in 71% yield; 1H NMR (CDCl3, δ ppm): 9.77 and 9.52 8.50 (s, 1H, meso-H); 5.90 [q, 1H, CH(o-hexyl)-CH3]; 5.22 (dd, 2H, 2H, exocyclic ring); 4.41 (q, 1H, 18H); 4.28 (d, 1H, 17-H); 3.75 (q, 2H, CH2CH3); 3.62, 3.25 and 3.20 (each s, 3H, ring CH3); 2.10 (3H, CHCH3); 1.80 (d, 3H, 18-CH3): 1.75 (t, 3H, CH2CH3); 2.75–2.12 (several m, CH2CH2CO2H); 0.76–1.30 [several m, 10H, (CH2)5] 0.43 and −1.78 (each s, 1H, NH). Mass calculated for: C39H48N4O4: 636. Found: 637 (M+1).


EXAMPLE 3

Preparation of Purpurin-18 methyl ester


Chlorin e6 trimethyl ester (175 mg) was dissolved in pyridine (15 mL) and the reaction temperature was maintained at 50° C. A slow stream of air was passed through the solution and potassium tert-butoxide (Aldrich, 2.5 mL, 1.0 M) was added. The reaction mixture was stirred at room temperature for 20 min. It was the quenched with glacial acetic acid (5 mL), poured in water, extracted with dichloromethane (2×100 mL). The dichloromethane layer was washed with 2 M HCl (50 mL), then washed with water again. The organic layer was separated and dried over anhydrous sodium sulfate. The residue obtained after evaporating the solvent was re-dissolved in dichloromethane, treated with diazomethane, purified by silica column chromatography, eluting with 2% acetone in dichloromethane and crystallized from dichloromethane/hexane. Yield 80%; 1H NMR (CDCl3, δ ppm): 9.60, 9.35 and 8.60 (each s, 1H, meso-H); 7.90 (m, 1H, CH═CH2); 6.30 and 6.20 (each d, 1H, CH═CH2); 5.12 (d, 1H, 17-H); 4.40 (q, 1H, 18-H); 3.75 (s, 3H, CO2CH3); 3.65 (q, 2H, —CH2CH3); 3.60, 3.30 and 3.15 (each s, 3H, ring CH3); 2.80–1.90 (several m, —CH2CH2CO2CH3); 1.75 (d, 3h, 18-CH3); 1.60 (t, 3H, —CH2CH3); 0.20 and −0.90 (each br s, 1H, NH).


Since modifications will be apparent to those of skill in this art, it is intended that this invention be limited only by the scope of the appended claims.

Claims
  • 1. A process for the preparation of methyl pheophorbide-a, comprising treating chorin e6 trimethyl ester with a base in an aromatic solvent having a boiling point at least as high as 144° C., the boiling point of 2,6-lutidine.
  • 2. A process for the preparation of methyl pheophorbide-a, comprising: (a) treating chorin e6 trimethyl ester with a base in an aromatic solvent having a boiling point at least as high as 144° C., the boiling point of 2,6-lutidine to give methyl pheophorbide-a; and(b) without isolating the methyl pheophobide-a from the resulting reaction mixture, heating the methyl pheophorbide-a to a temperature sufficient to effect decarboxylation and saponification of the methyl pheophorbide-a.
  • 3. A process for the preparation of ether analogs of pyropheophorbide-a comprising: (a) treating chorin e6 trimethyl ester with a base in an aromatic solvent having a boiling point at least as high as 144° C., the boiling point of 2,6-lutidine to give methyl pheophorbide-a;(b) without isolating the methyl pheophobide-a from the resulting reaction mixture, heating the methyl pheophorbide-a to a temperature sufficient to effect decarboxylation and saponification of the methyl pheophorbide-a to give pheophorbide-a; and(c) treating the pyropheophorbide-a with an acid, followed by an alcohol under basic conditions to effect addition of the alcohol across a vinyl group.
  • 4. The process of claim 3, wherein the alcohol is 1-hexanol (n-hexyl alcohol) to obtain 3-devinyl-3-(hexyloxy)ethyl-pyropheophorbide-a (HPPH).
  • 5. A process for the preparation of purpurin-18, comprising: (a) treating chlorin e6 trimethyl ester with a base in an aromatic solvent in the presence of air to give purpurin-18 having a —CH2CH2COOH group.
  • 6. A process for the preparation of purpurinimides, comprising: (a) treating chlorin e6 trimethyl ester with a base in an aromatic solvent in the presence of air to give purpurin-18 having a —CH2CH2COOH group;(b) esterifying the —CH2CH2COOH group to obtain purpurin-18 ester; and(c) treating the esterified purpurin-18 with a primary amine.
  • 7. A process for the preparation of ether analogs of purpurinimides, comprising: (a) treating chlorin e6 trimethyl ester with a base in an aromatic solvent in the presence of air to give purpurin-18 having a —CH2CH2COOH group;(b) esterifying the —CH2CH2COOH group to obtain purpurin-18 ester;(c) treating the esterified purpurin-18 ester with a primary amine; and(d) treating the resulting purpurinimide with an acid, followed by an alcohol under basic conditions.
  • 8. A process for the preparation of purpurin-18 ester, comprising: (a) treating chlorin e6 trimethyl ester with a base in an aromatic solvent in the presence of air to give purpurin-18 having a —CH2CH2COOH group; and(b) esterifying the —CH2CH2COOH group.
  • 9. A process for the preparation of ether analogs of purpurin-18, comprising: treating the esterified purpurin-18 obtained by the steps of claim 8 with an acid, followed by treating with an alcohol under basic conditions.
  • 10. The method of claim 8 where the group is esterified using diazomethane to obtain purpurin 18 methyl ester.
  • 11. The method of claim 2 where the aromatic solvent is sym-collidine.
RELATED APPLICATIONS

Priority is claimed herein under 35 U.S.C. §119(e) to U.S. provisional patent application No. 60/393,617, filed Jul. 2, 2002, to Pandey et al., entitled “EFFICIENT SYNTHESIS OF PYROPHEOPHORBIDE A AND ITS DERIVATIVES.” The above-referenced application is incorporated herein by reference in its entirety.

STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH

This invention was made with funding from the National Institute of Health Grant Number NIH CA55792. The United States Government may have certain rights in this invention.

US Referenced Citations (270)
Number Name Date Kind
3710795 Higuchi et al. Jan 1973 A
3817837 Rubenstein et al. Jun 1974 A
3927193 Hansen et al. Dec 1975 A
RE28819 Thompson May 1976 E
4044126 Cook et al. Aug 1977 A
4328245 Yu et al. May 1982 A
4331647 Goldenberg May 1982 A
4348376 Goldenberg Sep 1982 A
4358603 Yu Nov 1982 A
4361544 Goldenberg Nov 1982 A
4364923 Cook et al. Dec 1982 A
4374925 Litman et al. Feb 1983 A
4409239 Yu Oct 1983 A
4410545 Yu et al. Oct 1983 A
4414209 Cook et al. Nov 1983 A
4444744 Goldenberg Apr 1984 A
4468457 Goldenberg et al. Aug 1984 A
4474893 Reading Oct 1984 A
4479895 Auditore-Hargreaves Oct 1984 A
4521762 Kapral Jun 1985 A
4522811 Eppstein et al. Jun 1985 A
4577636 Spears Mar 1986 A
4624846 Goldenberg Nov 1986 A
4649151 Dougherty et al. Mar 1987 A
4656186 Bommer et al. Apr 1987 A
4675338 Bommer et al. Jun 1987 A
4693885 Bommer et al. Sep 1987 A
4753958 Weinstein et al. Jun 1988 A
4818709 Primus et al. Apr 1989 A
4861876 Kessel Aug 1989 A
4866168 Dougherty et al. Sep 1989 A
4878891 Judy et al. Nov 1989 A
4889129 Dougherty et al. Dec 1989 A
4916221 Kumadaki et al. Apr 1990 A
4925736 Shikowitz May 1990 A
4932934 Dougherty et al. Jun 1990 A
4935498 Sessler et al. Jun 1990 A
4946778 Ladner et al. Aug 1990 A
4957481 Gatenby Sep 1990 A
4968715 Dougherty et al. Nov 1990 A
4997639 Aizawa et al. Mar 1991 A
5002962 Pandey et al. Mar 1991 A
5004811 Bommer et al. Apr 1991 A
5015463 Dougherty et al. May 1991 A
5028594 Carson Jul 1991 A
5028621 Dougherty et al. Jul 1991 A
5033252 Carter Jul 1991 A
5041078 Matthes et al. Aug 1991 A
5051415 Moran et al. Sep 1991 A
5052558 Carter Oct 1991 A
5053006 Watson Oct 1991 A
5059415 Neuwelt Oct 1991 A
5062431 Potter Nov 1991 A
5066274 Bommer et al. Nov 1991 A
5066291 Stewart Nov 1991 A
5074632 Potter Dec 1991 A
5093349 Pandey et al. Mar 1992 A
5095030 Levy et al. Mar 1992 A
5111821 Potter May 1992 A
5145863 Dougherty et al. Sep 1992 A
5171741 Dougherty Dec 1992 A
5173504 Dougherty Dec 1992 A
5190536 Wood et al. Mar 1993 A
5190966 Dougherty et al. Mar 1993 A
5198460 Pandey et al. Mar 1993 A
5205291 Potter Apr 1993 A
5216012 Morgan et al. Jun 1993 A
5219345 Potter Jun 1993 A
5222795 Hed Jun 1993 A
5225433 Dougherty et al. Jul 1993 A
5257970 Dougherty Nov 1993 A
5263925 Gilmore, Jr. et al. Nov 1993 A
5298018 Narciso, Jr. Mar 1994 A
5308861 Aizawa et al. May 1994 A
5314905 Pandey et al. May 1994 A
5323907 Kalvelage Jun 1994 A
5330741 Smith et al. Jul 1994 A
5344928 Masuya et al. Sep 1994 A
5368841 Trauner et al. Nov 1994 A
5403308 Wood et al. Apr 1995 A
5418130 Platz et al. May 1995 A
5430051 Aizawa et al. Jul 1995 A
5441531 Zarate et al. Aug 1995 A
5459159 Pandey et al. Oct 1995 A
5482698 Griffiths Jan 1996 A
5484803 Richter Jan 1996 A
5496308 Brown et al. Mar 1996 A
5498710 Pandey et al. Mar 1996 A
5500009 Mendes et al. Mar 1996 A
5503637 Kyricos et al. Apr 1996 A
5506255 Smith et al. Apr 1996 A
5514669 Selman May 1996 A
5525338 Goldenberg Jun 1996 A
5532171 Motsenbocker Jul 1996 A
5534506 Morgan et al. Jul 1996 A
5538945 Pallenberg et al. Jul 1996 A
5549660 Mendes et al. Aug 1996 A
5556612 Anderson et al. Sep 1996 A
5567409 Aizawa et al. Oct 1996 A
5571152 Chen et al. Nov 1996 A
5580896 Horwell et al. Dec 1996 A
5591847 Pandey et al. Jan 1997 A
5594136 Sessler et al. Jan 1997 A
5599923 Sessler et al. Feb 1997 A
5622983 Horwell et al. Apr 1997 A
5624798 Yamamoto et al. Apr 1997 A
5631281 Horwell et al. May 1997 A
5637311 Pallenberg Jun 1997 A
5648485 Dolphin et al. Jul 1997 A
5665328 Horan et al. Sep 1997 A
5671317 Weishaupt et al. Sep 1997 A
5688486 Watson et al. Nov 1997 A
5697902 Goldenberg Dec 1997 A
5698405 Goldenberg Dec 1997 A
5702432 Chen et al. Dec 1997 A
5703230 Boyle et al. Dec 1997 A
5705518 Richter et al. Jan 1998 A
5709874 Hanson et al. Jan 1998 A
5715837 Chen Feb 1998 A
5716595 Goldenberg Feb 1998 A
5736563 Richter Apr 1998 A
5741316 Chen et al. Apr 1998 A
5759542 Gurewich Jun 1998 A
5766234 Chen et al. Jun 1998 A
5770619 Richter et al. Jun 1998 A
5770730 Pandey et al. Jun 1998 A
5773977 Dougherty Jun 1998 A
5776093 Goldenberg Jul 1998 A
5776094 Goldenberg Jul 1998 A
5776095 Goldenberg Jul 1998 A
5782896 Chen et al. Jul 1998 A
5800478 Chen et al. Sep 1998 A
5814008 Chen et al. Sep 1998 A
5824080 Lamuraglia Oct 1998 A
5827186 Chen et al. Oct 1998 A
5829448 Fisher et al. Nov 1998 A
5831088 Dolphin et al. Nov 1998 A
5832931 Wachter et al. Nov 1998 A
5840674 Yatvin et al. Nov 1998 A
5851225 Lawandy Dec 1998 A
5860957 Jacobsen et al. Jan 1999 A
5864035 Pandey et al. Jan 1999 A
5865840 Chen Feb 1999 A
5876427 Chen et al. Mar 1999 A
5885557 Lentini Mar 1999 A
5886173 Hemmi et al. Mar 1999 A
5900252 Calanchi et al. May 1999 A
5913884 Trauner et al. Jun 1999 A
5921244 Chen et al. Jul 1999 A
5942534 Trauner et al. Aug 1999 A
5944748 Mager et al. Aug 1999 A
5945762 Chen et al. Aug 1999 A
5948433 Burton et al. Sep 1999 A
5952366 Pandey et al. Sep 1999 A
5957960 Chen et al. Sep 1999 A
5972366 Haynes et al. Oct 1999 A
5976535 Fritzberg et al. Nov 1999 A
5983134 Ostrow Nov 1999 A
5985307 Hanson et al. Nov 1999 A
5985317 Venkateshwaran et al. Nov 1999 A
5997569 Chen et al. Dec 1999 A
5997842 Chen Dec 1999 A
5998597 Fisher et al. Dec 1999 A
6004534 Langer et al. Dec 1999 A
6010715 Wick et al. Jan 2000 A
6015897 Theodore et al. Jan 2000 A
6017888 Pallenberg et al. Jan 2000 A
6022961 Yamamoto et al. Feb 2000 A
6024975 D'Angelo et al. Feb 2000 A
6028099 de Juan, Jr. Feb 2000 A
6036941 Bottiroli et al. Mar 2000 A
6039975 Shah et al. Mar 2000 A
6048359 Biel Apr 2000 A
6048736 Kosak Apr 2000 A
6051207 Klaveness et al. Apr 2000 A
6051702 Bird et al. Apr 2000 A
6060082 Chen et al. May 2000 A
6063108 Salansky et al. May 2000 A
6063777 Hikida et al. May 2000 A
6071495 Unger et al. Jun 2000 A
6080160 Chen et al. Jun 2000 A
6084717 Wood et al. Jul 2000 A
6090788 Lurie Jul 2000 A
6092531 Chen et al. Jul 2000 A
6096066 Chen et al. Aug 2000 A
6096289 Goldenberg Aug 2000 A
6100893 Ensz et al. Aug 2000 A
6103751 Pandey et al. Aug 2000 A
6107466 Hasan et al. Aug 2000 A
6117862 Margaron et al. Sep 2000 A
6120751 Unger Sep 2000 A
6123923 Unger et al. Sep 2000 A
6124342 Okamoto et al. Sep 2000 A
6131570 Schuster et al. Oct 2000 A
6138681 Chen et al. Oct 2000 A
6139865 Friend et al. Oct 2000 A
6152951 Hashimoto et al. Nov 2000 A
6156506 Yamamoto et al. Dec 2000 A
6162213 Stewart Dec 2000 A
6162242 Peyman Dec 2000 A
6167301 Flower et al. Dec 2000 A
6176842 Tachibana et al. Jan 2001 B1
6187030 Gart et al. Feb 2001 B1
6210425 Chen Apr 2001 B1
6217869 Meyer et al. Apr 2001 B1
RE37180 Mori et al. May 2001 E
6232295 Kayyem et al. May 2001 B1
6238426 Chen May 2001 B1
6242477 Okamoto et al. Jun 2001 B1
6253872 Neumann Jul 2001 B1
6256533 Yuzhakov et al. Jul 2001 B1
6261595 Stanley et al. Jul 2001 B1
6264914 Klaveness et al. Jul 2001 B1
6267983 Fujii et al. Jul 2001 B1
6268120 Platz et al. Jul 2001 B1
6271359 Norris et al. Aug 2001 B1
6273904 Chen et al. Aug 2001 B1
6274552 Tamarkin et al. Aug 2001 B1
6281611 Chen et al. Aug 2001 B1
6307147 Bird et al. Oct 2001 B1
6316652 Steliou Nov 2001 B1
6319273 Chen et al. Nov 2001 B1
6319488 Licha et al. Nov 2001 B1
6331175 Goldenberg Dec 2001 B1
6331744 Chen et al. Dec 2001 B1
6344050 Chen Feb 2002 B1
6350431 Snow et al. Feb 2002 B1
6387350 Goldenberg May 2002 B1
6406297 Raymond et al. Jun 2002 B1
6416531 Chen Jul 2002 B1
6454789 Chen et al. Sep 2002 B1
6482517 Anderson Nov 2002 B1
6489314 Ashley et al. Dec 2002 B1
6495585 Bellnier et al. Dec 2002 B1
6498945 Alfheim et al. Dec 2002 B1
6500816 Ekimoto et al. Dec 2002 B1
6511971 Gorun Jan 2003 B1
6514995 Zaleski et al. Feb 2003 B1
6515113 Raymond et al. Feb 2003 B1
6520669 Chen et al. Feb 2003 B1
6524552 Klaveness et al. Feb 2003 B1
6525088 Nagano et al. Feb 2003 B1
6527759 Tachibana et al. Mar 2003 B1
6534040 Pandey et al. Mar 2003 B1
6540980 Blumenthal et al. Apr 2003 B1
6554853 Chen Apr 2003 B1
6559374 Lindsey et al. May 2003 B1
6566517 Miura et al. May 2003 B1
6569846 Scherz et al. May 2003 B1
6572839 Sugita et al. Jun 2003 B1
6580228 Chen et al. Jun 2003 B1
6602274 Chen Aug 2003 B1
6624187 Pandey et al. Sep 2003 B1
6657351 Chen et al. Dec 2003 B1
20010022970 Dees et al. Sep 2001 A1
20020033192 Lindsey et al. Mar 2002 A1
20020049247 Chen Apr 2002 A1
20020087205 Chen Jul 2002 A1
20020127224 Chen Sep 2002 A1
20020127230 Chen Sep 2002 A1
20020128303 Bellnier et al. Sep 2002 A1
20020198576 Chen et al. Dec 2002 A1
20030018371 Chen Jan 2003 A1
20030030342 Chen et al. Feb 2003 A1
20030109813 Chen Jun 2003 A1
20030114434 Chen et al. Jun 2003 A1
20030167033 Chen et al. Sep 2003 A1
20030208249 Chen Nov 2003 A1
20040044197 Pandey et al. Mar 2004 A1
20040044198 Pandey et al. Mar 2004 A1
Foreign Referenced Citations (84)
Number Date Country
0120054 Mar 1984 EP
0161606 Nov 1985 EP
0243929 Nov 1987 EP
0423195 Apr 1991 EP
0425566 May 1991 EP
0450149 Oct 1991 EP
0468997 Feb 1992 EP
0510007 Oct 1992 EP
0682956 Nov 1995 EP
0765152 Apr 1997 EP
1110963 Jun 2001 EP
1131100 Sep 2001 EP
1146046 Oct 2001 EP
1164136 Dec 2001 EP
1238666 Sep 2002 EP
1256586 Nov 2002 EP
1334748 Aug 2003 EP
4218002 Jul 1992 JP
6105921 Apr 1994 JP
2001335578 Apr 2001 JP
200220389 Jan 2002 JP
2002325853 Nov 2002 JP
2003146989 May 2003 JP
8401382 Apr 1984 WO
9000392 Jan 1990 WO
9000895 Feb 1990 WO
9012573 Nov 1990 WO
9110474 Jul 1991 WO
9313769 Jul 1993 WO
9409851 May 1994 WO
9427594 Dec 1994 WO
9505214 Feb 1995 WO
9532206 Nov 1995 WO
9535085 Dec 1995 WO
9637255 Nov 1996 WO
9639144 Dec 1996 WO
9701559 Jan 1997 WO
9732520 Sep 1997 WO
9732885 Sep 1997 WO
9804317 Feb 1998 WO
9806456 Feb 1998 WO
9808565 Mar 1998 WO
9814243 Apr 1998 WO
9824371 Jun 1998 WO
9824510 Jun 1998 WO
9832491 Jul 1998 WO
9832492 Jul 1998 WO
9832493 Jul 1998 WO
9846130 Oct 1998 WO
9850034 Nov 1998 WO
9856302 Dec 1998 WO
9918879 Apr 1999 WO
9920346 Apr 1999 WO
9939769 Aug 1999 WO
9952565 Oct 1999 WO
9958149 Nov 1999 WO
9966988 Dec 1999 WO
9967248 Dec 1999 WO
9967249 Dec 1999 WO
0015296 Mar 2000 WO
0036983 Jun 2000 WO
0041725 Jul 2000 WO
0041726 Jul 2000 WO
0041727 Jul 2000 WO
0041768 Jul 2000 WO
0061584 Oct 2000 WO
0103770 Jan 2001 WO
0105316 Jan 2001 WO
0115694 Mar 2001 WO
0143825 Jun 2001 WO
0151087 Jul 2001 WO
0174398 Oct 2001 WO
0178216 Oct 2001 WO
0178458 Oct 2001 WO
0198708 Dec 2001 WO
0217690 Feb 2002 WO
02098882 Dec 2002 WO
03029494 Apr 2003 WO
03050082 Jun 2003 WO
03052793 Jun 2003 WO
03056407 Jul 2003 WO
03061696 Jul 2003 WO
2004002476 Jan 2004 WO
2004005289 Jan 2004 WO
Related Publications (1)
Number Date Country
20040044198 A1 Mar 2004 US
Provisional Applications (1)
Number Date Country
60393617 Jul 2002 US